West Receives Exhibitor Award at INTERPHEX 2022 for Proprietary DeltaCubetm Modeling Platform

The DeltaCubetm Modeling Platform is an analytics platform aimed at container closure system (CCS) selection, optimization, and usage

EXTON, Pa., May 24, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced it received the Biotech Innovation Award for the DeltaCubetm Modeling Platform at the INTERPHEX 2022 Technical Conference in New York City.

"West is honored to receive an INTERPHEX 2022 Exhibitor Award recognizing the innovation of our DeltaCubetm Modeling Platform," said Chris Ryan, Senior Vice President, Containment and Glass Systems. "By supporting drug development and addressing containment earlier in the process, we can ensure needed drugs get safely to patients quicker. This tool provides a solution for the industry to reduce risk and accelerate development during the early-stage vial container closure system (CCS) selection and usage."

The DeltaCubetm Modeling Platform, a secure online vial integrity software modeling platform designed to help developers make more confident decisions about their container closure systems (CCS), uses a big-data approach, built on 90-plus years of CCS and container closure integrity (CCI) experience. The DeltaCubetm modeling platform provides an efficient and cost-effective tool to guide vial, stopper and seal combination selection based on fit, and supports the troubleshooting of defects or CCI failures due to component dimensional issues.

For more information about West, please visit our website: www.westpharma.com. To learn more about DeltaCube, click here.

For more information about INTERPHEX 2022 and the Exhibitor Award, please visit INTERPHEX's Exhibitor Awards website: www.interphex.com/en-us/exhibit/exhibitor-awards.html.

Forward-Looking Statements
Certain forward-looking statements are included in this press release. They use words such as "ensure," "reduce," "accelerate," and other similar terminology. These statements reflect management's current expectations regarding future events and operating performance and speak only as of the date of this release. There is no certainty that actual results will be achieved in-line with current expectations. Specifically, there is no certainty that the DeltaCubetm Modeling Platform will achieve any particular result. These forward-looking statements involve a number of risks and uncertainties. The following are some of the factors that could cause our actual results to differ materially from those expressed in or underlying our forward-looking statements: customer decisions to move forward with our new products and product categories; dependence on third-party suppliers and partners; and the ability to meet development milestones with key customers. These important factors are not all inclusive. For a description of certain additional factors that could cause West's future results to differ from those expressed in any such forward-looking statements, see Item 1A, entitled "Risk Factors," in West's Annual Report on Form 10-K for the year ended December 31, 2021. Except as required by law or regulation, West undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.

About West
West Pharmaceutical Services, Inc. is a leading provider of innovative, high-quality injectable solutions and services. As a trusted partner to established and emerging drug developers, West helps ensure the safe, effective containment and delivery of life-saving and life-enhancing medicines for patients. With approximately 10,000 team members across 50 sites worldwide, West helps support our customers by delivering over 45 billion components and devices each year.

Headquartered in Exton, Pennsylvania, and in business for nearly a century, West in its fiscal year 2021 generated $2.83 billion in net sales. West is traded on the New York Stock Exchange (NYSE: WST) and is included on the Standard & Poor's 500 index. For more information, visit www.westpharma.com.

All trademarks and registered trademarks used in this release are the property of West Pharmaceutical Services, Inc. or its subsidiaries, in the United States and other jurisdictions, unless otherwise noted.

SOURCE West Pharmaceutical Services, Inc.